Allogene Therapeutics, Inc. announced the virtual unveiling of its manufacturing facility, Cell Forge 1 (“CF1”), located in Newark, California. The 136,000-square-foot facility is designed to support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products for blood cancers and solid tumors. The virtual platform, designed to create an interactive and engaging CF1 virtual experience, includes welcome remarks from Allogene's President, Chief Executive Officer and Co-Founder, David Chang, M.D., Ph.D., corporate and scientific videos, a 360° virtual tour of the facility, and a patient gallery.

CF1 includes modular production suites, which are flexible and adaptable for growth. It also includes space for quality control testing, an environmental testing lab, and an advanced data system infrastructure, as well as administrative and warehouse space. Environmental sustainability was a key element of building design, including features that allow for energy savings, water conservation, and reduced greenhouse gas emissions.

CF1 is designed to be a fully electric facility 100% powered by renewable solar and wind power aimed at earning LEED Gold certification for design and operation.